Gastrointestinal hormones as potential adjuvant treatment of exocrine pancreatic adenocarcinoma

William E. Fisher, Peter Muscarella, Laszlo G. Boros, William J. Schirmer

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Conclusion. Gastrointestinal hormones and their antagonists can alter the growth of pancreatic adenocarcinoma in vitro and in vivo. The potential clinical benefit of this approach deserves further study. Background. Epithelial cell growth is normally under hormonal control. Hormones also affect the growth of many epithelial cancers, and this fact is used to modify tumor growth. Pancreatic epithelial cell growth is under the influence of gastrointestinal hormones. This article reviews experiments designed to determine the effect of gastrointestinal hormones on the growth of pancreatic adenocarcinoma. Methods. Eighty-eight articles were identified from a Medline search using the terms pancreatic adenocarcinoma and the individual names of gastrointestinal hormones. The experimental design and results of these studies are reviewed. Results. In general, somatostatin, vasoactive intestinal polypeptide, pancreatic polypeptide, and pancreastatin inhibit pancreatic adenocarcinoma growth. Cholecystokinin, secretin, bombesin, gastrin, EGF, TGF-α, insulin, and IGF-1 have a growth-promoting effect.

Original languageEnglish (US)
Pages (from-to)169-180
Number of pages12
JournalInternational Journal of Pancreatology
Issue number3
StatePublished - 1998
Externally publishedYes


  • Gastrointestinal hormones
  • Pancreatic adenocarcinoma

ASJC Scopus subject areas

  • Oncology
  • Endocrinology
  • Gastroenterology


Dive into the research topics of 'Gastrointestinal hormones as potential adjuvant treatment of exocrine pancreatic adenocarcinoma'. Together they form a unique fingerprint.

Cite this